• Moshe S. Torem


This chapter provides a review of the various psychotropic medications and benefits of their use in the treatment of patients with dissociative identity disorder (DID). Psychopharmacology in the broad perspective includes the study of the effects of psychoactive drugs on the human mind, including the patient’s thoughts, feelings, physical sensations, fantasies, activities and behavior applied in day-to-day living. In general, it is important to state that currently there is no one specific medication or combination of medications that cure patients with a dissociative disorder. However, the use of psychotropic medications can be quite helpful by providing the following benefits:
  1. 1.

    Reduce the intensity of debilitating symptoms such as anxiety, depression, poor concentration, insomnia, restlessness, nightmares, panic states, exaggerated startle response, and phobias.

  2. 2.

    Improve the patient’s mental state and attention focus to be more amenable and ready to benefit from psychotherapeutic interventions.

  3. 3.

    Provide the benefit of psychopharmalogical interventions in patients who have the comorbidity of a dissociative disorder with another psychiatric disorder such as major depression, bipolar disorder, panic disorder, obsessive-compulsive disorder, and so forth.



Obstructive Sleep Apnea Sleep Apnea Psychotropic Medication Panic Disorder Posttraumatic Stress Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amrein, R., Allen, S. R., Guentert, T. W, Hartmann, D., Lorscheid, T, Schoerlin, M. P, & Vranesic, D. (1989). Pharmacology of reversible MAOI. British Journal of Psychiatry, 144, 66–71.Google Scholar
  2. Amrein, R., Guntert, T. W, Dingemanse, J., Lorscheid, T, Stabl, M., & Schmid-Burgk, W. (1992). Interactions of moclobemide with concomitantly administered medication: Evidence from pharmacological and clinical studies. Psychopharmacology, 106, S24 - S31.PubMedCrossRefGoogle Scholar
  3. Barkin, R., Braun, B. G., & Kluft, R. P. (1986). The dilemma of drug therapy for multiple personality disorder. In B. G. Braun (Ed.), The treatment of multiple personality disorder (pp. 107–132 ). Washington, DC: American Psychiatric Press.Google Scholar
  4. Braun, B. G. (Ed.) (1986). The treatment of multiple personality disorder. Washington, DC: American Psychiatric Press.Google Scholar
  5. Braun, B. G. (1990a). Unusual medication regimens in the treatment of dissociative disorder patients: Part I. Noradrenergic agents. Dissociation, 3, 144–150.Google Scholar
  6. Braun, B. G. (1990b). The use of naltrexone in the treatment of dissociative disorder patients. In B. G. Braun (Ed.), Seventh International Conference on Multiple Personality and Dissociative States (p. 20 ). Rush University Department of Psychiatry, Chicago, IL.Google Scholar
  7. Chu, J. (1995). Successful use if Risperidone (Risperdal) in the treatment of DID patients. Personal communication.Google Scholar
  8. Coons, P. M. (1986). Treatment progress in 20 patients with multiple personality disorder. Journal of Nervous and Mental Disorders, 174, 715–721.CrossRefGoogle Scholar
  9. Evans, E. J. (1985). Expectancy, therapeutic instructions, and the placebo response. In L. White, B. Tursky, and G. E. Schwartz (Eds.), Placebo: Theory, research and mechanisms (pp. 215–228 ). New York: Guilford.Google Scholar
  10. Fesler, E A. (1991). Valproate in combat-related post-traumatic stress disorder. Journal of Clinical Psychiatry, 52 (9), 361–364.PubMedGoogle Scholar
  11. Fichtner, C. G., Kuhlman, D. T, Gruenfeld, M. J., Hughes, J. R. (1990). Decreased episodic violence and increased control of dissociation in a carbamazepine-treated case of multiple personality. Biological Psychiatry, 27, 1045–1052.PubMedCrossRefGoogle Scholar
  12. Friedman, M. J. (1988). Toward rational pharmacotherapy for posttraumatic stress disorder. American Journal of Psychiatry, 145, 281–285.PubMedGoogle Scholar
  13. Friedman, M. J. (1991). Biological approaches to the diagnosis and treatment of posttraumatic stress disorder. Journal of Traumatic Stress, 4, 67–91.CrossRefGoogle Scholar
  14. Friedman, M. J. (1993). Psychobiological and pharmacological approaches to treatment. In J. T Wilson and B. Raphael (Eds.), International handbook of traumatic stress syndromes (pp. 785–794 ). New York: Plenum.CrossRefGoogle Scholar
  15. Friedman, M. J. (1994). Biological and pharmacological aspects of the treatment of PTSD. In M. B. Williams and J. F. Sommor (Eds.), Handbook of posttraumatic therapy (pp. 495–509 ). Westport, CT: Greenwood.Google Scholar
  16. Gainer, M. J. & Torem, M. S. (1994). Clinical corner: Sleep and dissociation-New findings. ISSD Newsletter, 12 (4), 8.Google Scholar
  17. Griest, J. H., Jefferson, J. W, Kobak, K. A., Katzelnick, D. J., Serlin, R. C. (1995). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Archives in General Psychiatry, 52, 53.CrossRefGoogle Scholar
  18. Jacobsen, F. M. (1991). Possible augmentation of antidepressant response by buspirone. Journal of Clinical Psychiatry, 52, 217–220.PubMedGoogle Scholar
  19. Kluft, R. P. (1984). Aspects of the treatment of multiple personality disorder. Psychiatric Annals, 14, 51–55.Google Scholar
  20. Kluft, R. P. (1985). The treatment of multiple personality disorder (MPD). Current concepts. In E F. Flach (Ed.), Directions in psychiatry (pp. 1–10 ). New York, Hatherleigh.Google Scholar
  21. Kluft, R. P. (1989). Playing for time: Temporizing techniques in the treatment of multiple personality disorder. American Journal of Clinical Hypnosis, 32, 90–97.PubMedCrossRefGoogle Scholar
  22. Larson, J. K., Gjerris, A., Holm, P, Anderson, J., Bille, A., Christensen, E. M., Hoyer, E., Jensen, H., Mejlhede, A., & Langagergaard, A. (1991). Moclobemide in depression: A randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. Acta Psychiatrica Scandinavica, 84 (6), 564–570.CrossRefGoogle Scholar
  23. Lipper, S., Davidson, J. R. T, Grady, T A., Edinger, J. D., Hammett, E. B., Mahomey, S. L., & Cavenar, J. O. (1986). Preliminary study of carbamazepine in posttraumatic stress disorder. Psychosomatics, 27, 849–854.PubMedCrossRefGoogle Scholar
  24. Loewenstein, R. J., Hornstein, N., Barber, B. (1988). Open trial of clonazepam in the treatment of posttraumatic stress symptoms in MPD. Dissociation, 1, 3–12.Google Scholar
  25. Loewenstein, R. J. (1991). Rational Psychopharmacology in the treatment of multiple personality disorder. The Psychiatric Clinics of North America, 14, 721–740.PubMedGoogle Scholar
  26. Montgomery, S. (1993). Venlafaxine: a new dimension in antidepressant pharmacotherapy. Journal of Clinical Psychiatry, 54 (3), 119–126.Google Scholar
  27. Orne, M. T. (1959). Hypnosis: Artifact and essence. Journal of Abnormal Psychology, 58, 277–299.PubMedCrossRefGoogle Scholar
  28. Putnam, F. W. (1986). The treatment of multiple personality: State of the art. In B. G. Braun (Ed.), Treatment of multiple personality disorder (pp. 175–198 ). Washington, DC: American Psychiatric Press.Google Scholar
  29. Putnam, E. W. (1989). Diagnosis and treatment of multiple personality disorder. New York: Guilford. Ross, C. A. (1989). Multiple personality disorder Diagnosis, clinical features, and treatment. New York: Wiley.Google Scholar
  30. Rossel, L. & Moll, E. (1990). Moclobemide versus tranylcypromine in the treatment of depressions. Acta Psychiatrica Scandinavica, Supplementum, 360, 61–62.Google Scholar
  31. Shapiro, A. K. (1960). A contribution to a history of the placebo effect. Behavioral Science, 5, 109–135.CrossRefGoogle Scholar
  32. Shapiro, A. K. (1968). Semantics of the placebo. Psychiatric Quarterly, 42, 653–696.PubMedCrossRefGoogle Scholar
  33. Shapiro, A. K. & Morris, L. A. (1978). The placebo effect in medical and psychological therapies. In S. L.Google Scholar
  34. Garfield & A. E. Bergin, (Eds.), Handbook of psychotherapy and behavior change (2nd ed., pp.Google Scholar
  35. 369-.
    ). New York: Wiley.Google Scholar
  36. Sharpley, A. L., Walsh, A. E., & Cowen, P. J. (1992). Nefazodone—a novel antidepressant—may increase REM sleep. Biological Psychiatry, 31, 1070–1073.PubMedCrossRefGoogle Scholar
  37. Spiegel, D. (1986). Dissociation, double binds, and posttraumatic stress. In B. G. Braun (Ed.), The treatment of multiple personality disorder (pp. 61–77 ). Washington DC: American Psychiatric Press.Google Scholar
  38. Torem, M. S., & Gainer, M. J. (1993). Treatment of MPD: A systems approach. Paper presented at the Eighth Regional Conference on Trauma, Dissociation, and Multiple Personality, April 23–24, Akron, OH.Google Scholar
  39. Torem, M. S., & Gainer, M. J. (1995). The center core: Imagery for experiencing the unifying self. Hypnos, 22, 125–131.Google Scholar
  40. van der Kolk, B. A. (1987). The drug treatment of post-traumatic stress disorder. Journal of Affective Disorders, 13, 203–213.Google Scholar
  41. Versiana, M., Nardi, A. E., Mundim, F D., Alves, A. B., Liebowitz, M. R., & Amrein, R. (1992). Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine. British Journal of Psychiatry, 161, 353–360.CrossRefGoogle Scholar
  42. Wolin, R. E. (1994). Successful use of risperidone (Risperdal) in the treatment of patients with dissociative disorders. Personal communication.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Moshe S. Torem
    • 1
    • 2
  1. 1.Department of Psychiatry and Behavioral SciencesAkron General Medical CenterAkronUSA
  2. 2.Department of PsychiatryNortheastern Ohio Universities College of MedicineAkronUSA

Personalised recommendations